Joseph Payne, Arcturus CEO
April 20, 2022 10:43 AM EDTUpdated 10:55 AM
R&D
Coronavirus

Arc­turus slides on PhI­II Covid-19 vac­cine da­ta, sig­ni­fy­ing the strug­gle in pro­duc­ing fol­low-up shots

Max Gelman

Senior Editor

As Covid-19 vac­cine de­mand sags in the US with on­ly about a third of adults hav­ing re­ceived their first boost­er shot, new da­ta just don …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Leg­end names a pres­i­dent of Carvyk­ti; No­vo Nordisk's top North Amer­i­ca ex­ec is step­ping down

Athi­ra gives up on lead Alzheimer’s drug, switch­es tack to ALS

Nkar­ta drops an­oth­er can­cer pro­gram as it leans in­to au­toim­mune dis­ease

Se­nior As­traZeneca ex­ec de­tained in Chi­na amid wider in­ves­ti­ga­tion

Pfiz­er to in­vest $1B in Chi­na over next five years — re­ports

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times